Cellular Repair & Recovery
WolverineBPC-157 / TB-500
BPC-157 and TB-500 blend
Research context
This preparation combines BPC-157 and TB-500, which act through different reported mechanisms — VEGFR2-associated angiogenic signalling and G-actin sequestration respectively. Each is characterised independently.
Common assays: Component identity by LC-MS · Purity per component · Migration assays
Specification
| Designation | Peptide blend |
|---|---|
| Full name | BPC-157 and TB-500 blend |
| Components | BPC-157 · TB-500 |
| Formats | 10 mL Vial · 15 mL Advanced Liquid Peptide Spray |
| Solubility | Bacteriostatic water, sterile water |
| Storage | Lyophilised: −20 °C. Reconstituted: 2–8 °C. |
| Current lot | BT1010N0626 → |
BPC-157 / TB-500 COA: certificates of analysis by lot
5 lots of BPC-157 / TB-500 have a published certificate of analysis from AxisPharm, LLC, an independent laboratory. Each certificate reports the laboratory's results for that lot.
| Lot | Format | Purity (HPLC-UV) | Reported |
|---|---|---|---|
| BT1010N0626 | 10 mg / 10 mg Spray | 99.4% | 2026-06-18 |
| BT1010VAS0526 | 10 mg / 10 mg Vial | >99.5% | 2026-05-11 |
| BT1010VCS0126 | 10 mg / 10 mg Vial | >99.6% | 2026-02-20 |
| BT1010N1025 | 10 mg / 10 mg Spray | >99.0% | 2025-11-20 |
| BT1010V1125 | 10 mg / 10 mg Vial | >99.0% | 2025-11-03 |
Common questions
Do BPC-157 and TB-500 act through the same mechanism?
No. The published literature associates BPC-157 with VEGFR2 and nitric oxide pathway signalling, and TB-500 with G-actin sequestration and cytoskeletal reorganisation.
Where can I see the BPC-157 / TB-500 certificate of analysis?
Every published BPC-157 / TB-500 lot has its own certificate page on this site, listed under "BPC-157 / TB-500 COA" above. There are 5 published lots; the most recent, lot BT1010N0626, was reported on 2026-06-18 at 99.4% purity by HPLC-UV. The certificates are issued by AxisPharm, LLC, an independent laboratory.
Components, blends and pathway
Related compounds
BPC-157
Body Protection Compound-157
A synthetic pentadecapeptide derived from a gastric juice sequence, studied in migration and angiogenesis models.
TB-500
Thymosin beta-4 fragment
A synthetic fragment corresponding to the actin-binding domain of thymosin beta-4.
KLOW
BPC-157 / TB-500 / GHK-Cu / KPV
A prepared four-component blend combining repair-signalling and cytokine-pathway compounds.
KPV
Lys-Pro-Val tripeptide
The C-terminal tripeptide of α-melanocyte-stimulating hormone, studied in NF-κB signalling.